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Background: Influenza B viruses are classified into two main lineages: Yamagata-like and Victoria-like, which differ
antigenically and phylogenetically. To understand the evolution of influenza B viruses in South East Asia as well as
to determine the vaccine efficacy, we genetically characterised gene segments 4, 6 and 8 from non-tissue culture
adapted influenza B viruses detected in Singapore from 2004 to 2009.
Methods: vRNA were extracted from the nasopharyngeal swabs or nasal washes of SAF servicemen displaying
febrile and respiratory symptoms, and subjected to PCR assay to test for the presence of influenza B virus. The
PCR-positive specimens were next subjected to sequencing of the full gene segments 4 (HA), 6 (NA/NB) and 8
(NS1/NEP). The nucleotide sequences were aligned together with that of other specimens isolated from South East
Asia as well as the vaccine strains. Phylogenetic trees of each gene segment were constructed and the amino acid
alignments were analysed.
Results: A majority of the Singaporean specimens analysed in this study, from 2004–2009, had gene segment 4
from the Victoria-like lineage and gene segment 6 from Yamagata-like lineage. Some of these specimens had both
gene segments from the Yamagata lineage and this resulted in several vaccine mismatches. Gene segment 8 from
majority of these specimens clustered separately from both the Yamagata and Victoria strains. The HA protein of
most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was
not dominant prior to 2000. No amino acid substitution conferring drug-resistance was found in either the HA or
NA proteins.
Conclusions: The presence of both lineages co-circulating post 2000, suggests that a trivalent vaccine is not
enough to confer immunity to the general public, strongly endorsing the inclusion of both lineages in the vaccine.
Several amino acid substitutions were observed, prompting in depth functional analyses.
Keywords: Influenza B, Phylogenetic analysis, Viral evolution, Surveillance, Singapore, Circulating lineage,
Vaccine efficiencyBackground
Influenza B viruses belong to the Orthomyxoviridae
family and has a genome of 8 negative, single-stranded
segments. Although Influenza B viruses circulates primar-
ily in humans several reports had suggested that seals can
serve as a possible animal reservoir for the virus [1-3].
The virus was initially isolated in 1940 [4] and since the* Correspondence: ephtbh@nus.edu.sg
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unless otherwise stated.early 1980s two distinct lineages have predominated;
B/Victoria/2/87-like and B/Yamagata/16/88-like viruses
[5,6]. In the 1980s, the Victoria lineage was dominant and
this was followed by the Yamagata lineage in the 1990s.
Since the year 2000, both lineages have been detected at
similar frequencies globally [7,8].
The clinical symptoms associated with influenza B
virus infection are generally similar to that of influ-
enza A virus [9-11]. However, a few studies have
shown that influenza B infections are linked with severe
symptoms [10,12-16]. Throughout 2012, influenza A virus
infections dominated the total influenza cases repor-
ted globally and regionally by the Global Influenzatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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int/influenza/gisrs_laboratory/en/). Amongst influenza B
infections, the GISRS reported that the Victoria-lineage
caused more infections that the Yamagata-lineage in 2012
[17]. When analysed separately, the South East Asia re-
gion showed that influenza B virus was responsible for
more than a third of all influenza infections. At the global
level, influenza B viruses accounted for more than half of
influenza infections between weeks 4–18 and 45–52
of 2012 [18]. Majority of these influenza B virus specimens
isolated belonged to the Victoria lineage [19].
The two most abundant glycoproteins of influenza B
viruses are hemagglutinin (HA) and neuraminidase (NA)
[20]. Through the activity of both its subunits, the HA
protein functions in receptor binding and in membrane
fusion, facilitating viral entry [20,21]. Unlike the HA pro-
tein, the NA functions late in the viral replication, cleaving
the α–(2,3) and α–(2,6) glycosidic links between the ter-
minal sialic acids moieties of glycoproteins, allowing for
successful viral shedding [22,23]. Both proteins present as
structural epitopes which are recognised by the host im-
mune system [24]. This selective pressure results in these
proteins undergoing significant antigenic drift, resulting in
antigenic variation from one epidemic to be different from
the next. Genetic reassortment of the gene segments occur
frequently between the two main influenza B lineages. This
means that circulating viruses may have different combina-



















2004 Southern B/Hong Kong/330/2001
The composition of the TIV is recommended bi-annually by the WHO. The influenza
B virus currently circulating. The last column of this table lists the abbreviation usedSingapore, being a tropical country, experiences a higher
prevalence of influenza viruses than most temperate coun-
tries. Its tropical conditions as well as being a commercial
hub has allowed for influenza viruses to circulate all year
round with peaks between April-July and November-
January [27-29]. Between the years of 1972–1999, there
have been 25 reported influenza epidemics and four of
which were caused by influenza B viruses. However, two
out of these epidemics had an influenza A strain co-
circulating with the predominant influenza B strain
[29]. An epidemiological survey of respiratory infections
amongst Singaporean military recruits found that up to a
third of influenza infections were caused by influenza B
infections [30]. The emergence of the pandemic H1N1 of
swine origin in 2009 resulted in a suppression of influenza
B virus circulation in Singapore. Since 2010, the preva-
lence of influenza B infections seems almost reciprocal to
the prevalence of the influenza A viruses in Singapore
[31]. For the past 5 years, a minimum of 20% of all influ-
enza infections in Singapore were attributed to influenza
B viruses [32]. It has been estimated that influenza B
infections are responsible for 14.8 out of 100000 deaths in
tropical countries yearly [28]. With the current trend in
increasing resistance to treatment [33], and with an esti-
mated of 50% vaccine efficacy in Singapore [34], this num-
ber is anticipated to increase.
This study aims to determine the nucleotide sequences
of the circulating influenza B virus strains in Singaporeuenza vaccine (TIV) from 2004-2013
Lineage Abbreviation
Yamagata Vacc1213N B Wisconsin 01 2010






Yamagata Vacc0809NS B Florida 4 2006
Yamagata
Yamagata




Yamagata Vacc0506N B Jiangsu 10 2003
Yamagata Vacc0504N 05S B Shanghai 361 2002
Yamagata
Victoria Vacc04S B Hong Kong 330 2001
B component is often decided by HI inhibition assay of the prevalent influenza
for each vaccine strain throughout this report.
Figure 1 (See legend on next page.)
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Figure 1 Phylogenetic tree of the HA gene segment of Singaporean specimens isolated from 2004 to 2009. The HA sequences of these
specimens were aligned together with the HA gene segments of B/Lee/40, B/Yamagata/16/88, B/Victoria/2/87, the vaccine strains from 2004–
2013 (Table 1) and the HA gene segments of Singaporean strains isolated in 1964, 1979, 1991, 1994, 1998, 2010 and 2011. Representative strains
of influenza B from countries within SEA, such as Hong Kong, Philippines, Taiwan, Thailand, Malaysia and Myanmar, isolated post 2000 available
from GenBank were included in this alignment as well. Lineages were marked by the labelled brackets.
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ture adapted. By comparing the lineage identity of these
strains to that of the vaccine strains, we would be able
to observe for any mismatches which may result in
inadequate immunological protection. Differences in the
nucleotide and amino acid sequence would allow us to
observe the evolutionary mechanisms of influenza B vi-
ruses and understand the divergence of the circulating
strains from the vaccine strains. Furthermore, phylo-
genetic analysis of current and previously sequenced
Singaporean strains can allow us to track the reassort-
ment of influenza B virus over the last 50 years. Lastly,
analysis of the mutation pattern of these circulating
strains may provide greater insights in drug resistance
and antibody recognition. We believe that this is the first
study to genetically characterise non egg/tissue-culture
adapted influenza B virus strains in Singapore. While
the samples collected in this study were from the
military, it is important to note that a large percentage of
Singaporean males are enrolled into the military at the age
of 18. This makes the results obtained in this study repre-
sentative of national surveillance [30].
Results
Sequence and phylogenetic analysis of gene segments 4
and 6
Viral RNA (vRNA) was extracted directly from clinical
specimens and used as template for PCR amplification
and sequencing. A list of all the specimens sequenced in
this study can be found in Additional file 1: Table S1.
Three overlapping DNA fragments corresponding to the
open reading frames of the HA and NA genes were
PCR-amplified and sequenced. The resulting contig was
then aligned with the rest of the clinical specimens as
well as representative strains from SEA and the vaccine
strains of 2004–2013 (Table 1) to produce the phylogen-
etic trees (Figures 1 and 2). Out of the 46 clinical speci-
mens isolated in this study, the HA gene was sequenced
from 42 while the NA gene from 44. The HA gene of
the clinical specimens sequenced in this study displayed
a similarity of 83.5%-99.9% while that for the NA gene;
84.5%-99.8%, when compared amongst themselves.
As shown in Figure 1, the gene segment 4 of the speci-
mens sequenced in this study clustered within the
Victoria-like lineage together with other recent Singapore
strains, except for DSO_010147_2007. Generally, the spec-
imens clustered according to their year of isolation. Thespecimen DSO_010147_2007 was isolated in year 2007,
but clustered within the Yamagata lineage, together with
some of the recent Singapore strains isolated in 2010 and
2011. Figure 2 shows the phylogenetic tree of gene seg-
ment 6 of the same specimens and shows that they fall
within the Yamagata lineage. Similar to that in Figure 1,
most of these specimens clustered according to their year
of isolation (Figures 1 and 2).
Sequence and phylogenetic analysis of gene segment 8
To facilitate future functional analysis, gene segment 8
was sequenced as described in the methods section. The
36 clinical specimens yielding sequence for gene segment
8 in this study displayed 89.8%-100% similarity. A phylo-
genetic tree of gene segment 8 was generated similarly to
gene segments 4 and 6 (Figure 3). As reported previously,
gene segment 8 of B/Victoria/2/87 and B/Yamagata/16/88
did not split into 2 separate clusters, unlike gene segments
4 and 6, in Figures 1 and 2 [25]. Instead, both strains fell
under cluster II, suggesting similar ancestry (Figure 3)
[25,35-37]. The majority of the Singaporean specimens
clustered in cluster III, together with most of the regional
specimens and the vaccine strains. Interestingly, 7 of the
specimens isolated in 2004 clustered together with B/Lee/
40 in cluster I (Figure 3). This is the only instance where a
gene segment clusters with B/Lee/40 (Figures 1, 2 and 3).
HA protein sequence analysis
The main neutralising epitope of HA of the Victoria-like
strains lies between residues 178–185 and this is known
as the ‘tip’ (Table 2) [38]. The amino acid sequence of
the specimens sequenced in this study as well as other
Singaporean strains of Victoria lineage is identical to
B/Victoria/87. Only two substitutions were observed
in the vaccine strains: B/Hong Kong/330/2001 (E179D) and
B/Brisbane/60/2008 (N180K). The ‘tip’ epitope is not as
conserved amongst the Singapore strains of the Yamagata
lineage (Table 2). For example, DSO_010147_2007, the only
Yamagata-like specimen sequenced in this study has a
N181Y substitution which was previously unseen in any
sequence but in the vaccine strain B/Wisconsin/01/2010,
suggesting that this substitution was newly introduced.
Table 3 lists the variation displayed at the main neutra-
lising epitope of the HA from Yamagata-like strains
known as the ‘loop’, between aa 156–164 [39]. DSO_
010147_2007 has 2 substitutions in this epitope: V161A
and R164K.
Figure 2 (See legend on next page.)
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Figure 2 Phylogenetic tree of the NA gene segment of Singaporean specimens isolated from 2004 to 2009. The NA sequences of these
specimens were aligned together with the NA gene segments of B/Lee/40, B/Yamagata/16/88, B/Victoria/2/87, the vaccine strains from 2004–
2013 (Table 1) and the NA gene segments of Singaporean strains isolated in 1979, 1991, 1994, 1998, 2010 and 2011. Representative strains of
influenza B from countries within SEA, such as Hong Kong, Philippines, Taiwan, Thailand, Malaysia and Myanmar, isolated post 2000 available from
GenBank were included in this alignment as well. Lineages were marked by the labelled brackets.
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in most of the specimens isolated in Japan post 2002.
Prior to 2002, aa 211–213 displayed a variety of se-
quences (NEA, KET, NEN and NET) [40]. Table 4 lists
the sequence of the strains analysed in this study. All of
the specimens sequenced had this glycosylation site
except for DSO_050629_2005 (NEI). Interestingly, the
HA gene segment of DSO_050629_2005 belonged to the
Victoria lineage and this glycosylation site was initially
found only in Japanese strains belonging to the same
lineage. The same glycosylation site was observed even
in Singaporean specimens isolated in 2010–2011. B/
Singapore/222/1979 and B/Singapore/1964 did not have
this glycosylation site (TET and NEI), while, 3 of the 5
Singaporean specimens isolated in the 90s contained the
glycosylation site (NKT) sequences.
Three separate epitopes on the HA of influenza B have
been identified which are targets of binding of antibodies
CR8033, CR8071 and CR9114. These three antibodies
were able to provide immunological protection in mice
when administered after influenza B viral infection in
mice [41]. The epitope recognised by CR8033 exists on
the HA trimer, which overlaps the conserved receptor
binding site (Table 5). Specimens of Yamagata lineage
displayed variability at positions 151, 165, 177, 215 and
218, while only two specimens of the Victoria lineage
showed variability at position 151. Uniquely, while N165
was conserved in all the Victoria strains, the Yamagata
strains listed in Table 5 could harbour an Isoleucine,
Serine, Aspartic Acid or a Lysine. Similarly, N218 was
conserved in Victoria strains but variability was observed
in the Yamagata strains (Serine, Lysine and Threonine)
(Table 5). R177 was conserved in Singaporean Yamagata
strains isolated between 1991 and 1998, while specimens
before and after that period contained a Lysine. Notably,
P176, which when substituted to a Glutamic acid resul-
ted to poor susceptibility to CR8033, was conserved in
all the specimens listed in Table 5.
A K53E substitution within the CR8071 epitope has
been shown to produce mutant viruses with reduced
susceptibility to the antibody. This substitution was not
observed in any of the specimens listed except that
DSO_010151_2005 had an Arginine at this position.
This substitution does not result in charge reversal as in
K53E and may not result in any significant antigenic
change (Table 6). It has also been noted that strains with
a Histidine at position 40 rather than a Tyrosine are noteffectively neutralized by CR8071. Antibody CR9114 binds
to a conserved region within the stem region of the HA
protein of both influenza A and B viruses [41]. Singaporean
specimens isolated in 2010 and 2011 of the Yamagata
lineage displayed K323R and DSO_050599_2005 of the
Victoria lineage, displayed I380V (Table 7).
NA protein sequence analysis
An important functional site located on the NA protein is
the calcium binding site which lies between aa 318–350
[42]. Amino acid substitutions in the calcium binding site
are listed in Table 8. Most of the substitutions listed are
conservative, (E320D, D329N, and R346S) suggesting a
positive selection for this site. For example, E320D is
seen in five other specimens, B/Myanmar/M107/2007,
B/Myanmar/M254/2007, B/Taiwan/14/2007, B/Taiwan/
2894/2006 and B/Hong Kong/259/2010. D329 is observed
in B/Malaysia/27127/2004, B/Malaysia/1899839/2007,
B/Malaysia/1919534/2008, B/Taiwan/2171/2004 and B/
Taiwan/71523/2007. K343E is observed in three speci-
mens (B/Singapore/68C/2010, B/Singapore/83C/2011 and
B/Singapore/87H/2011). R345S substitution is seen in the
rest of the specimens analysed in the NA phylogen-
etic tree except for B/Bangkok/141/1994 which har-
boured a Leucine at that same position. Each of the amino
acids listed are hydrophilic and are substituted with an-
other hydrophilic residue, except for R345L in B/Bangkok/
141/1994.
NB protein sequence analysis
Gene segment 6 encodes for the short, hydrophobic NB
protein, of which no function has yet been assigned. All
of the amino acid substitutions within aa 19–40, the
postulated transmembrane domain, were conservative,
keeping this stretch hydrophobic (Table 9) [43-46].
NS1 and NEP protein sequence analysis
Gene segment 8 encodes 2 proteins: the NS1 and the
NEP proteins. The NS1 and NEP proteins of the seven
specimens clustering in cluster I show similar amino
acid profiles to B/Lee/40. These amino acid substitutions
are not seen in the rest of the clinical specimens clustering
in cluster III (Figure 3 and Tables 10 and 11). The nuclear
localisation sequence (NLS) of the NS1 protein lies be-
tween aa 46–56 [47]. Within the NLS only two amino
acid substitutions are observed (H49N and R53K). These
Figure 3 (See legend on next page.)
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Figure 3 Phylogenetic tree of the NS gene segment of Singaporean specimens isolated from 2004 to 2009. The NS sequences of these
specimens were aligned together with the NS gene segments of B/Lee/40, B/Yamagata/16/88, B/Victoria/2/87, the vaccine strains from 2004–
2013 (Table 1) and the NA gene segments of Singaporean strains isolated in 1991, 1994 and 1998. Owing to the lack of NS gene sequences of
recent strains from SEA, the NS alignment also included strains from the United States, Egypt and New Zealand which were isolated post 2000.
The 3 different clusters of NS1 were labelled Clades I, II and III.
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(Table 10).
Influenza B NS1 has been shown to bind to and inhibit
human ISG15 [48]. 19 amino acids in the first 101 resi-
dues of influenza B NS1 have been identified as directly
interacting with ISG15 [49]. Out of these 19 amino
acids, the specimens sequenced in this study displayed
variation at positions 34, 97 and 101 (Table 10). Speci-
mens of cluster I showed sequence identity to B/Lee/40
at these positions. F34L is seen in all the specimens in
clades II and III, while I97V is only seen in the 3 speci-
mens listed in Table 10 and in B/Bangkok/141/1994.Table 2 Amino acid substitution of the HA ‘Tip’ epitope
Yamagata ‘loop’
156 164
Yamagata 88 G S C P N V T S R
DSO 010147 2007 . . . . . A . . K
Vacc0405N 05S B Jilin 20 2003 . . . . . A . . K
Vacc0506N B Jiangsu 10 2003 R . . . . A . . K
Vacc0809NS B Florida 4 2006 . . . . . A . . K
Vacc1213N B Wisconsin 01 2010 . . . . . A . . K
Singapore 2010-2011 . . . . . A . . K
B Singapore 04 1991 . . . . . . . N .
B Singapore 11 1994 . . . . . A . . .
B Singapore 22 1998 . . . . . A . . K
B Singapore 31 1998 . . . . . A . . K
B Singapore 35 1998 . . . . . A . . .
B Singapore 222 1979 . . . . . . . N G
B Singapore 1964 . . . . . . . N G
Victoria 87 G S C P N V T N G
DSO Victoria . . . . . . . . .
DSO 050629 2005 . . . . . . . . .
Vacc04S B Hong Kong 330 2001 . . . . . . . . .
Vacc0608NS B Malaysia 2506 2004 . . . . . . . . .
Vacc0912NS B Brisbane 60 2008 . . . . . I . . .
Singapore 2010-2011 . . . . . . . . .
Lee40 . . . . . . A . .
The ‘Tip’ epitope of the HA protein is the main neutralising epitope of viruses
belonging to the Victoria lineage. Specimens listed under B Yamagata 16 88
belong to the Yamagata lineage while specimens listed under B Victoria 2 87
belong to the Victoria lineage. DSO Victoria: specimens sequenced in this
study belonging to the Victoria lineage. Identical amino acids are marked by a
dot (.) and deletions are denoted by a dash (−).E101G is only seen in DSO_050143_2005 and
DSO_050540_2005.
Amino acid substitution of the NEP
Amino acids of positions 35, 66, 80 and 98 of the NEP
display sequence variability as listed. I: Specimens clus-
tering in cluster I of the NS phylogenetic tree. II: Speci-
mens clustering in cluster II of the NS phylogenetic tree.
III: Specimens clustering in cluster III of the NS phylo-
genetic tree. Rest of DSO Specimens: rest of specimens
sequenced in this study not individually listed in this
table. Identical amino acids are marked by a dot (.).Table 3 Amino acid substitution of the HA ‘Loop’ epitope
Victoria ‘tip’
178 185
Yamagata 88 ̶ D N ̶ K T A T
DSO 010147 2007 ̶ . . Y . N . .
Vacc0405N 05S B Jilin 20 2003 ̶ . . . . N . .
Vacc0506N B Jiangsu 10 2003 ̶ . . . . N . .
Vacc0809NS B Florida 4 2006 ̶ . . . . N . .
Vacc1213N B Wisconsin 01 2010 ̶ . . Y . N . .
Singapore 2010-2011 ̶ . . Y . N . .
B Singapore 04 1991 ̶ . . - . . . .
B Singapore 11 1994 ̶ . . N . . . .
B Singapore 22 1998 ̶ . . N . . . .
B Singapore 31 1998 ̶ . . N . . . .
B Singapore 35 1998 ̶ . . N . . . .
B Singapore 222 1979 ̶ . ̶ N . . . .
B Singapore 1964 ̶ N K N . . . R
Victoria 87 N D N N K T A T
DSO Victoria . . . . . . . .
DSO 050629 2005 . . . . . . . .
Vacc04S B Hong Kong 330 2001 . E . . . . . .
Vacc0608NS B Malaysia 2506 2004 . . . . . . . .
Vacc0912NS B Brisbane 60 2008 . . K . . . . .
Singapore 2010-2011 . . K . . . . .
Lee40 ̶ . . . . . . I
The ‘Loop’ epitope of the HA protein is the main neutralising epitope of
viruses belonging to the Yamagata lineage. Specimens listed under B
Yamagata 16 88 belong to the Yamagata lineage while specimens listed
under B Victoria 2 87 belong to the Victoria lineage. DSO Victoria: specimens
sequenced in this study belonging to the Victoria lineage. Identical amino
acids are marked by a dot (.) and deletions are denoted by a dash (−).
Table 4 Amino acid substitution of a potential
glycosylation site at position 211-213
HA glycosylation site
211 213
Yamagata 88 D K T
DSO 010147 2007 N . .
Vacc0405N 05S B Jilin 20 2003 N . .
Vacc0506N B Jiangsu 10 2003 N . .
Vacc0809NS B Florida 4 2006 . . .
Vacc1213N B Wisconsin 01 2010 N . .
Singapore 2010-2011 N . .
B Singapore 04 1991 N . I
B Singapore 11 1994 N . .
B Singapore 22 1998 N . N
B Singapore 31 1998 N . .
B Singapore 35 1998 N . .
B Singapore 222 1979 T E .
B Singapore 1964 N E I
Victoria 87 N E A
DSO Victoria . . T
DSO 050629 2005 . . I
Vacc04S B Hong Kong 330 2001 S . T
Vacc0608NS B Malaysia 2506 2004 . . X
Vacc0912NS B Brisbane 60 2008 . . T
Singapore 2010-2011 . . T
Lee40 D K T
Specimens listed under B Yamagata 16 88 belong to the Yamagata lineage
while specimens listed under B Victoria 2 87 belong to the Victoria lineage.
DSO Victoria: specimens sequenced in this study belonging to the Victoria
lineage. Identical amino acids are marked by a dot (.) and X refers to an
unknown amino acid.
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seen in the specimens listed in Table 11 as well as B/
Malaysia/33772/2005. While A66 was specific to the cluster
I specimens, S80 was also observed in B/Hawaii/11/2004,
B/Hawaii/13/2004 and B/Hawaii/33/2004. I98 was also
present in B/Bangkok/141/1994 and B/Seoul/1163/2004
(Table 11).
Discussion
There have been very few studies on influenza B virus epi-
demiology in Singapore. Among the earliest Singaporean
strain sequenced, B/Singapore/1964, had gene segment 4
from the Yamagata lineage. No sequence information of
gene segment 4 was available for this strain. Another early
strain, B/Singapore/222/1979, had gene segment 4 belong-
ing to the Yamagata lineage and gene segment 7 from the
Victoria lineage. The Singaporean specimens isolated
in the 1990s had both gene segments belonging to the
Yamagata lineage (Figures 1 and 2). Reports of influenza Bviruses isolated between 1990 and 1999, have suggested
that the dominant lineage of that era (by HI-tests and se-
quencing of the HA gene alone) were from the Yamagata
lineage, with few outbreaks of the Victoria lineage detec-
ted in Europe [4,50-53]. The Victoria lineage, however,
was suggested to be the emergent stain in 1987 in South
China and Japan [5,26].
Post 2004, the majority of the Singaporean specimens
had gene segment 4 from the Victoria lineage and gene
segment 6 from the Yamagata lineage; however a substan-
tial minority had both gene segments from the Yamagata
lineage, such as DSO_010147_2007. In a retrospective
study, it was shown that prior to 2002, Yamagata-like viru-
ses were dominant in South East Asia (SEA) [54]. During
the year 2002, most of the viruses circulating in the same
region were Victoria-like, while post-2002 both lineages
have been circulating almost too equal frequencies. This
suggests that viruses of the Victoria lineage could have
emerged from South China and Japan and managed to
spread to Singapore by 2002, as supported by previous
studies [7,8].
Vaccine studies in children as well as in laboratory
animals had previously showed that the vaccination with
the Yamagata lineage of influenza B does not provide
immunity against the viruses of the Victoria lineage
[55,56]. The data from these studies also suggested that
post 2000, influenza B viruses of both lineages were co-
circulating simultaneously. This further suggests that in-
cluding one influenza B strain in the bi-annual trivalent
vaccine is clearly insufficient to protect the entire po-
pulation against influenza B infection. For example,
B/Malaysia/2506/2004, the vaccine strain suggested for
2006–2008, had gene segments 4 and 6 from the Victoria
and Yamagata lineages respectively. Viruses of this re-
assortment order represent the majority of the Singaporean
specimens sequenced in this study. However, vaccinated
individuals infected with viruses similar to DSO_010147_
2007 would probably not be protected by the B/Malaysia/
2506/2004 vaccine. The same case can be argued for the
vaccine strain B/Brisbane/60/2008, which is similar in reas-
sortment to B/Malaysia/2506/2004; but 3 out of the 11
Singaporean specimens isolated in 2010–2011 did not
match this re-assortment pattern (Figures 1 and 2) further
suggesting that the protection from the vaccine strain was
not adequate. Similar observation was previously made
where 95% of the influenza viruses circulating in 2007–
2008 were of the Yamagata lineage while the vaccine strain
was of the Victoria lineage [57]. In another report, it was
shown that between the years 1999–2000, the circulating
strains only match the vaccine strains in 5 out of the
10 years period [58]. The data from this study agrees with
the latest injunction to include two strains of influenza B
viruses in the biannual vaccine so as ensure that the public
is adequately immunised by both lineages [58-60].
Table 5 Amino acid substitution of the CR8033 epitope
CR8033 (Head)
154 155 157 165 175 177 178 215 218 219 255 256 258
Yamagata 88 T S S N V R - Q N L L P S
DSO 010147 2007 . . . I . K . . . . . . .
Vacc0405N 05S B Jilin 20 2003 . . . S . K . P . . . . .
Vacc0506N B Jiangsu 10 2003 . . . S . K . . . . . . .
Vacc0809NS B Florida 4 2006 . . . S . K . . . . . . .
Vacc1213N B Wisconsin 01 2010 . . . I . K . . S . . . .
Singapore 2010–2011 (Yam) . . . I . K . . . . . . .
B Singapore 04 1991 . . . D . . . . . . . . .
B Singapore 11 1994 . . . S . . . . . . . . .
B Singapore 22 1998 . . . S . . . . . . . . .
B Singapore 31 1998 . . . S . . . . . . . . .
B Singapore 35 1998 . . . S . . . . . . . . .
B Singapore 222 1979 . . . N . K . . K . . . .
B Singapore 1964 . . . K . K . . T . . Q .
Victoria 87 T S S N V K N Q K L L P S
DSO Victoria . . . . . . . . . . . . .
Vacc04S B Hong Kong 330 2001 . . . . . . . . . . . . .
Vacc0608NS B Malaysia 2506 2004 . . . . . . . . . . . . .
Vacc0912NS B Brisbane 60 2008 . . . . . . . . . . . . .
Singapore 2010–2011 (Vic) . . . . . . . . . . . . .
Lee40 T S S N I K - Q R L L K S
Specimens listed under B Yamagata 16 88 belong to the Yamagata lineage while specimens listed under B Victoria 2 87 belong to the Victoria lineage. DSO
Victoria: specimens sequenced in this study belonging to the Victoria lineage. Identical amino acids are marked by a dot (.) and X refers to an unknown
amino acid.
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http://www.biomedcentral.com/1756-0500/7/863Gene segment 8 of B/Victoria/2/87 and B/Yamagata/
16/88 clustered together in cluster II, suggesting similar
ancestry (Figure 3). It is also possible that the split in the
lineages occurred before the emergence of these two
strains. Evidence for this lies in the clustering pattern of
B/Singapore/222/1979 and B/Singapore/1964 in Figures 1
and 2. Both of these specimens were isolated prior to
the emergence of the ancestor strains, yet still cluster
within the Yamagata or Victoria lineages.
The V161A substitution in the HA protein has not
been reported but strains carrying K164 have been
shown to have the same reactivity with strains displaying
R164. Strains displaying R156 and G164 have been docu-
mented with the inability to react with the antibody [39].
Interestingly vaccine strain B/Jiangsu/10/2003 has R156
while B/Singapore/222/1979 and B/Singapore/1964 have
G164. Further functional studies will be required to
determine if these two substitutions result in a change in
antibody binding.
The data from Table 7, pertaining to the glycosylation
site at aa 211–213, suggests that position 211 of the HA
protein is probably exposed, and located on the exteriorof the globular protein. The folding of the protein at this
position is also independent of its lineage. All the vaccine
strains except for B/Florida/4/2006 and B/Hong Kong/
330/2001 did not contain this potential glycosylation site.
The amino acid at position 213 for B/Malaysia/2506/2004
is unknown, as the codon at that position has the nu-
cleotide sequence ayc (where y = c or t) therefore is it not
possible to determine if this protein has the glycosylation
site (Table 7). Further analysis of the specimens used to
construct the HA phylogenetic tree revealed that all
of the regional specimens contained this potential gly-
cosylation site, except for B/Taiwan/72068/2004 (KKT),
B/Taiwan/91061/2005 (SET), B/Taiwan/2894/2006 (DET),
B/Taiwan/71523/2007 (SKT), B/Malaysia/1749642/2007
(SET) and B/Hong Kong/310/2004 (KET). It is possible
that this glycosylation site originated in Japan prior to its
spread worldwide; however since this glycosylation site
was also seen in Singapore as early as 1994, it suggests
that the origin of this glycosylation site occurred inde-
pendent to the previous one. Studies in influenza A vi-
ruses have led to the suggestion that an introduction of a
glycosylation site may mask an antibody-binding epitope,
Table 6 Amino acid substitution of the CR8071 epitope
CR8071 (Head)
52 53 55 56 67 73 74 75 76 77 100 101 105 300 301 302 303 305
Yamagata 88 T K H F K L N C C T H E V G S L P I
DSO 010147 2007 . . Y . . . . . . . . . . . . . . .
Vacc0405N 05S B Jilin 20 2003 . . Y . . . . . . . . . . . . . . .
Vacc0506N B Jiangsu 10 2003 . . Y . . . . . . . . . . . . . . .
Vacc0809NS B Florida 4 2006 . . Y . . . . . . . . . . . . . . .
Vacc1213N B Wisconsin 01 2010 . . Y . . . . . . . . . . . . . . .
Singapore 2010-2011 . . Y . . . . . . . . . . . . . . .
B Singapore 04 1991 . . . . . . . . . . . . . . . . . .
B Singapore 11 1994 . . . . . . . . . . . . . . . . . .
B Singapore 22 1998 . . Y . . . . . . . . . . . . . . .
B Singapore 31 1998 . . . . . . . . . . . . . . . . . .
B Singapore 35 1998 . . . . . . . . . . . . . . . . . .
B Singapore 222 1979 . . . . . . . . . . . . . . . . . .
B Singapore 1964 . . . . . . . . . . . . . . . . . .
Victoria 87 T K H F K L N C C T H E V G S L P I
DSO Victoria . . . . . . . . . . . . . . . . . .
DSO Victoria 2009 I . . . . . . . . . . . . . . . .
DSO 010151 2005 . R . . . . . . . . . . . . . . . .
DSO 090114 2004 . . . . . F . . . . . . . . . . . .
Vacc04S B Hong Kong 330 2001 . . . . . . . . . . . . . . . . . .
Vacc0608NS B Malaysia 2506 2004 . . . . . . . . . . . . . . . . . .
Vacc0912NS B Brisbane 60 2008 . . . . . . . . . . . . . . . . . .
B Singapore 1H 2010 . . . . . P . . . . . . . . . . . .
B Singapore 17H 2010 . . . . . P . . . . . . . . . . . .
B Singapore 32C 2010 . . . . . P . . . . . . . . . . . .
B Singapore 57H 2010 . . . . . P . . . . . . . . . . . .
B Singapore 65H 2010 . . . . . P . . . . . . . . . . . .
B Singapore 71H 2010 . . . . . P . . . . . . . . . . . .
B Singapore 77C 2011 . . . . . . . . . . . . . . . . . .
B Singapore 90C 2011 . . . . . P . . . . . . . . . . . .
Lee40 T K H F K F N C C T H E A G S L P I
Specimens listed under B Yamagata 16 88 belong to the Yamagata lineage while specimens listed under B Victoria 2 87 belong to the Victoria lineage. DSO
Victoria: specimens sequenced in this study belonging to the Victoria lineage. Identical amino acids are marked by a dot (.) amino acid.
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http://www.biomedcentral.com/1756-0500/7/863leading to an antigenic change [61]. This further suggests
that a similar masking may take place at this glycosylation
position for the influenza B virus HA protein.
The data from Table 6 suggests that CR8071 would
be effective in neutralizing current specimens of the
Yamagata lineage rather than the Victoria lineage. Pos-
ition 73 also displayed sequence variability only amongst
the specimens of the Victoria lineage, where specimens
displayed a Leucine, Phenylalanine or Proline, further
investigations have to be carried out to determine if any
change in antibody binding would result (Table 6).Both substitutions listed in Table 7 have not been pre-
viously reported but their conservative nature, suggests
there might not be any change in antibody binding. This
conserved stem region shown in several reports and ours
suggests that vaccines eliciting antibodies against such
epitopes may provide long lasting protection against
both influenza A and B viruses [41,62] (Table 7).
This K343E substitution observed in the NA protein is
interesting as it represents a reversal in the charge in a
domain which requires conservation of charge for calcium
ion binding, as evidenced by their difference in pKa values:
Table 7 Amino acid substitution of the CR9117 epitope
CR9117 (Stalk)
43 45 46 47 321 322 323 380 381 382 383 398 400 403 404 407 408 410 411 414 418
Yamagata 88 G I P L S K P I A G W A L T Q I N I T L S
DSO 010147 2007 . . . . . . . . . . . . . . . . . . . . .
Vacc0405N 05S B Jilin 20 2003 . . . . . . . . . . . . . . . . . . . . .
Vacc0506N B Jiangsu 10 2003 . . . . . . . . . . . . . . . . . . . . .
Vacc0809NS B Florida 4 2006 . . . . . . . . . . . . . . . . . . . . .
Vacc1213N B Wisconsin 01 2010 . . . . . . . . . . . . . . . . . . . . .
Singapore 2010-2011 . . . . . R . . . . . . . . . . . . . . .
B Singapore 04 1991 . . . . . . . . . . . . . . . . . . . . .
B Singapore 11 1994 . . . . . . . . . . . . . . . . . . . . .
B Singapore 22 1998 . . . . . . . . . . . . . . . . . . . . .
B Singapore 31 1998 . . . . . . . . . . . . . . . . . . . . .
B Singapore 35 1998 . . . . . . . . . . . . . . . . . . . . .
B Singapore 222 1979 . . . . . . . . . . . . . . . . . . . . .
B Singapore 1964 . . . . . . . . . . . . X X X X X X X X X
Victoria 87 G I P L S K P I A G W A L T Q I N I T L S
DSO Victoria . . . . . . . . . . . . . . . . . . . . .
DSO 050629 2005 . . . . . . . . . . . . . . . . . . . . .
DSO 050599 2005 . . . . . . . V . . . . . . . . . . . . .
Vacc04S B Hong Kong 330 2001 . . . . . . . . . . . . . . . . . . . . .
Vacc0608NS B Malaysia 2506
2004
. . . . . . . . . . . . . . . . . . . . .
Vacc0912NS B Brisbane 60 2008 . . . . . . . . . . . . . . . . . . . . .
Singapore 2010-2011 . . . . . . . . . . . . . . . . . . . . .
Lee40 G I P L S K P I A G W A L T Q I N I T L S
Specimens listed under B Yamagata 16 88 belong to the Yamagata lineage while specimens listed under B Victoria 2 87 belong to the Victoria lineage. DSO Victoria:
specimens sequenced in this study belonging to the Victoria lineage. Identical amino acids are marked by a dot (.) and X information unavailable.
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http://www.biomedcentral.com/1756-0500/7/863Glutamic Acid-4.07 and Lysine-10.53. This difference in
pKa could possibly affect calcium binding. The selection
for the calcium binding site of the NA protein to remain
hydrophilic strongly suggests conservation of phenotype
(Table 8). However, functional and structural assays are
needed in order to determine if these substitutions do
have an actual effect on calcium binding.
None of the previously cited amino acid changes asso-
ciated to neuraminidase inhibitor (NAI) resistance were
found in this study in either the HA or NA proteins
[33,63-72].
While the function of the NB protein is still unknown, aa
19–40 have been shown to constitute its transmembrane
domain [43-46]. The data from this study strengthens the
view that the function of NB is membrane-associated since
there seems to be a selective pressure in maintaining aa
19–40 hydrophobic (Table 9).
P67S and L92I in the NB were only seen in Singaporean
strain isolated in 2009 (Table 9). Neither one of thesesubstitutions occur independently of each other, suggest-
ing that both these amino acids might act in concert in
the function of NB.
While R53K in the NS1 protein is conservative, H49N
results in the substitution of a basic amino acid to a neu-
trally charged amino acid (Table 10). This might result
in a change in the ability of NS1 to localise to the nucleus.
Further functional analysis has to be carried out to deter-
mine if the amino acid substitutions listed in Tables 10
and 11 result in a change of NS1 binding to ISG15 or
NEP’s ability to transport vRNPs out of the nucleus (Ta-
bles 10 and 11).
Conclusions
Phylogenetic analyses of clinical specimens reveal that
majority of influenza B strains detected between the
years of 2004–2009 were reassortants with gene seg-
ments 4 and 6 belonging to the Victoria and Yamagata
lineages respectively. This data corroborates with the
Table 8 Amino acid substitution of the NA calcium
binding site
NA calcium binding site
320 329 343 345
B Yamagata 16 1988 E D K R
Rest of DSO Specimens . . . S
DSO 050528 2005 D . . S
DSO 070214 2006 D . . S
DSO 020114 2007 D . . S
DSO 020132 2007 D . . S
DSO 020147 2007 D . . S
DSO 010147 2007 D N . S
B Singapore 1H 2010 D . . S
B Singapore 32C 2010 D . . S
B Singapore 17H 2010 D . . S
B Singapore 57H 2010 D . . S
B Singapore 65H 2010 D . . S
B Singapore 68C 2010 . N E S
B Singapore 77C 2011 D . . S
B Singapore 71H 2011 D . . S
B Singapore 90C 2011 N . . S
B Singapore 83C 2011 . N E S
B Singapore 87H 2011 . N E S
B Singapore 04 1991 . . . .
B Singapore 11 1994 . . . S
B Singapore 22 1998 . . . S
B Singapore 31 1998 . . . S
B Singapore 35 1991 . . . S
B Singapore 222 1979 . . . L
Vacc04S B Hong Kong 330 2001 . . . S
Vacc0405N 05S B Jilin 20 2003 . . . S
Vacc0405N 05S B Shanghai 361 2002 . . . S
Vacc0608NS B Malaysia 2506 2004 . . . S
Vacc0506N B Jiangsu 10 2003 . . . S
Vacc0809NS B Florida 4 2006 . N . S
Vacc0912NS B Brisbane 60 2008 D N . S
Vacc1213N B Wisconsin 01 2010 . N . S
B Lee 40 K D K L
B Victoria 02 1987 E D K R
4 amino acid positions within the calcium binding site display variability
throughout the NA protein alignment; 320, 329, 343 and 345. Specimens listed
under B Yamagata 16 88 belong to the Yamagata. Rest of DSO Specimens:
rest of specimens sequenced in this study not individually listed in this table.
Identical amino acids are marked by a dot (.).
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http://www.biomedcentral.com/1756-0500/7/863Singaporean specimens isolated in 2010–2011. Several
vaccine mismatches were observed in years 2007, 2010
and 2011, strongly proving the need for a quadrivalent
vaccine.The NS1 gene of specimens detected in 2004 show a
strong similarity to B/Lee/40 NS1, unseen in other speci-
mens. This phenomenon could suggest that B/Yamagata/
88 and B/Victoria/87 are not representative of the split in
influenza B evolution and that a third cluster similar to B/
Lee/40 is still in circulation, albeit being a minority.
No amino acid substitution relating to drug resistance
has been identified in the specimens sequenced in this
study. Other amino acid substitutions highlighted in this
study require further functional analysis to determine
their ability to affect the protein’s phenotype.
We believe, to the best of our knowledge, that this is
the first study of influenza B epidemiology in South East
Asia to focus on sequence analysis of gene segments 4, 6
and 8. Gene segments 4 and 6 were chosen as they
encode the HA and NA proteins which are the most
antigenic proteins of the virus, while gene segment 8
encodes the NS1 protein which is the main protein
involved in pathogenesis. The clinical specimens analysed
were sequenced directly from VTM and were not passaged
through eggs or tissue culture to avoid tissue culture/egg
adaptations. This avoids tissue culture/egg adaptations,
giving us an accurate representation of the circulating
sequences of influenza B viruses.
Methods
Virus
The influenza B virus, strain B/Lee/40 (VR101) was pur-
chased from the American Type Culture Collection
(ATCC). The virus was stored in 1 ml aliquots in −80°C.
12 day old embryonated chicken eggs were infected with
B/Lee/40 for 48 hrs at 37°C, 5% CO2. Allantoic fluid was
harvested and clarified at 2000 rpm for 15 min. 1 ml ali-
quots of the clarified allantoic fluid were stored in −80°C.
Clinical specimens
Specimens were collected from the Singapore military
men who reported sick to the medical centres of various
camps between 2004 and 2009. Only individuals present-
ing a fever of greater than 38°C (oral temperature) with
cough and/or sore throat were recruited for the study.
Consenting patients displaying the abovementioned symp-
toms provided throat swabs or nasal swabs, which were
then re-suspended in viral transport medium (VTM), as
previously described [30]. These specimens are named
according to the following format; DSO_(numerical code)_
(year of collection). This study, reference 160D-7/404-3,
was approved by the Joint Medical Committee, Research,
of the Singapore Armed Forces [30].
Extraction of influenza B virus vRNA
Viral RNA (vRNA) was extracted using the RNeasy
minikit (Qiagen, Inc., Valencia, CA, USA) according to
manufacturer’s instructions. The extracted vRNA were
Table 9 Amino acid substitution of the NB protein
Transmembrane domain Ecto domain
21 22 24 29 30 31 34 35 43 48 67 92
B Yamagata 16 1988 V I T F T V T V F N P L
Rest of DSO Specimens I . . . I . . I P Y . .
DSO 070214 2006 I . I . I I . I L . . .
DSO 050091 2006 I . I . I I . I L . . .
DSO 020147 2007 I . I . I I . I L . . .
DSO 020132 2007 I . I . I I . I L . . .
DSO 020114 2007 I . I . I I . I L . . .
DSO 020113 2007 I . I . I I . I L . . .
DSO 050528 2005 I . . . I . . I P Y . F
DSO 0003 2009 I . . . I . . I . Y S I
DSO 0005 2009 I . . . I . . I . Y S I
DSO 0070 2009 I . . . I . . I . Y S I
DSO 0100 2009 I . . . I . . I . Y S I
B Singapore 04 1991 . T . L I . . . L Y . .
B Singapore 11 1994 A . . . . . . . . Y . .
B Singapore 22 1998 . . . . . . I I . Y . .
B Singapore 31 1998 . . . . . . I I . Y . .
B Singapore 35 1991 . . . . . . . I . Y . .
B Singapore 222 1979 . . . . . . . . . Y . .
Vacc04S B Hong Kong 330 2001 . . . L . . . . . . . F
Vacc0405N 05S B Jilin 20 2003 . . . . . . . I . . . .
Vacc0405N 05S B Shanghai 361 2002 . . . . . . . I . . . .
Vacc0608NS B Malaysia 2506 2004 I . . . I . . I P Y . .
Vacc0506N B Jiangsu 10 2003 . . . . . . . I . . . .
Vacc0809NS B Florida 4 2006 . . . . I . . I . . . .
Vacc0912NS B Brisbane 60 2008 . . . . I I . I L . . .
Vacc1213N B Wisconsin 01 2010 . . . . I . . I . . . .
B Lee 40 I I T L T V I V F N P L
B Victoria 02 1987 V I T L I V T V F N P L
Amino acid 21–35 correspond to the putative transmembrane domain of the NB protein while positions 43–92 are located on the ecto domain of the protein.
Specimens listed under B Yamagata 16 88 belong to the Yamagata. Rest of DSO Specimens: rest of specimens sequenced in this study not individually listed in
this table. Identical amino acids are marked by a dot (.).
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http://www.biomedcentral.com/1756-0500/7/863stored in −80°C until real-time PCR assays were perfor-
med as described in Seah et al., [30]. Only PCR-positive
specimens were used for sequencing of the HA and
NA genes.
Primers
Table 12 lists all the primers used in this study. Primers
were designed in-house by the alignment of HA, NA and
NS gene segments of influenza B isolated in Singapore
previously as available from NCBI database. Primers were
designed using BioEdit Software (See Table 13).cDNA synthesis
Complementary DNA synthesis was carried out for the
specimens using either the Transcriptor First-Strand
cDNA synthesis System for RT-PCR (Roche) with the
reverse transcription step carried out at 65°C for 30 mi-
nutes or the SuperScript II First-Strand cDNA Synthesis
Kit (Invitrogen) with UniB primer (Table 12) [73] and
with the reverse transcription step carried out at 42°C
for 1 hour. Other than the modifications mentioned, all
other steps were carried out according to manufacturer’s
instructions.
Table 10 Amino acid substitution of the NS1-NLS AND ISG15 binding site
NS1 nuclear localisation sequence ISG15 binding site
46 56 34 97 101
I B Lee 40 D R L H R L N R K L E F I E
DSO 090114 2004 . . . . . . . . . . . . . .
DSO 090124 2004 . . . . . . . . . . . . . .
DSO 090131 2004 . . . . . . . . . . . . . .
DSO 090133 2004 . . . . . . . . . . . . . .
DSO 090134 2004 . . . . . . . . . . . . . .
DSO 090136 2004 . . . . . . . . . . . . . .
DSO 090138 2004 . . . . . . . . . . . . . .
II B Yamagata 16 1988 . . . N . . . K . . . L V .
B Victoria 02 1987 . . . N . . . K . . . L . .
B Singapore 04 1991 . . . N . . . K . . . L V .
B Singapore 11 1994 . . . N . . . K . . . L V
III DSO 090117 2004 . . . N . . . K . . . L . .
DSO 050143 2005 . . . N . . . K . . . L . G
DSO 050540 2005 . . . N . . . K . . . L . G
Rest of DSO Specimens . . . N . . . K . . . L . .
B Singapore 22 1998 . . . N . . . K . . . L . .
B Singapore 31 1998 . . . N . . . K . . . L . .
B Singapore 35 1998 . . . N . . . K . . . L . .
Vacc04S B Hong Kong 330 2001 . . . N . . . K . . . L . .
Vacc0405N 05S B Jilin 20 2003 . . . N . . . K . . . L . .
Vacc0405N 05S B Shanghai 361 2002 . . . N . . . K . . . L . .
Vacc0608NS B Malaysia 2506 2004 . . . N . . . K . . . L . .
Vacc0506N B Jiangsu 10 2003 . . . N . . . K . . . L . .
Vacc0809NS B Florida 4 2006 . . . N . . . K . . . L . .
Vacc0912NS B Brisbane 60 2008 . . . N . . . K . . . L . .
Vacc1213N B Wisconsin 01 2010 . . . N . . . K . . . L . .
Amino acids 46–56 correspond to the NLS of the NS1 protein. I: Specimens clustering in cluster I of the NS phylogenetic tree. II: Specimens clustering in cluster II
of the NS phylogenetic tree. III: Specimens clustering in cluster III of the NS phylogenetic tree. Rest of DSO Specimens: rest of specimens sequenced in this study
not individually listed in this table. Identical amino acids are marked by a dot (.).
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The cDNA synthesized from above was used to PCR-
amplify the full HA gene segment using primers desig-
nated HA F and HA R [74] (Table 12) with the Platinum
Taq Polymerase High Fidelity kit (Invitrogen) using
touchdown PCR thermocycling conditions: initial denatur-
ation at 95C for 2 minutes, followed by 11 cycles of, 94C-
30 sec, 55C-30 sec (−1C/cycle) and 68°C for 2 min and
40 cycles of 94°C-30 sec, 48°C-sec, 68°C-2 min, a final
extension at 68°C for 10 minutes and holding temperature
at 4°C. A second round of PCR was performed to ob-
tain 3 overlapping fragments of the HA gene segment
using the primers; HA30F/HA749R, HA471F/HA1169R
and HA999/HA1840R (Table 12). The thermocyclingconditions for the amplification of all three of these
fragments are similar to that described above but with
an extension step of 1 min.
Neuraminidase (NA) gene
The full NA gene was PCR-amplified from cDNAs as
described for the full HA gene; except that the primers
used were NA F and NA R [74] (Table 1) using the same
enzyme and thermocycling conditions described. Again,
a second round of PCR was performed to obtain 3 overlap-
ping fragments of the NA gene segment using the primers;
NA21F/NA568R, NA361F/NA838R and NA716F/NA1505R
(Table 12). The thermocycling conditions for each pri-
mer sets required annealing temperatures of 45°C, 58°C
Table 11 Amino acid substitution of the NEP
NEP
35 66 80 98
I B Lee 40 S A S I
DSO 090114 2004 . . . .
DSO 090124 2004 . . . .
DSO 090131 2004 . . . .
DSO 090133 2004 . . . .
DSO 090134 2004 . . . .
DSO 090136 2004 . . . .
DSO 090138 2004 . . . .
II B Yamagata 16 1988 . V N .
B Victoria 02 1987 . V N .
B Singapore 04 1991 . V N .
B Singapore 11 1994 . V N .
III DSO 090117 2004 N V N V
DSO 0003 2009 N V N V
DSO 0005 2009 N V N V
DSO 0070 2009 N V N V
Rest of DSO Seq . V N V
B Singapore 22 1998 . V N V
B Singapore 31 1998 . V N V
B Singapore 35 1998 . V N V
B Singapore 04 1991 . V N V
Vacc04S B Hong Kong 330 2001 . V N V
Vacc0405N 05S B Jilin 20 2003 . V N V
Vacc0405N 05S B Shanghai 361 2002 . V N V
Vacc0608NS B Malaysia 2506 2004 . V N V
Vacc0506N B Jiangsu 10 2003 . V N V
Vacc0809NS B Florida 4 2006 . V N V
Vacc0912NS B Brisbane 60 2008 . V N V
Vacc1213N B Wisconsin 01 2010 . V N V
3 amino acids of the NS1 protein (34, 97 and 101) within the ISG15 binding
site display variability. I: Specimens clustering in cluster I of the NS
phylogenetic tree. II: Specimens clustering in cluster II of the NS phylogenetic
tree. III: Specimens clustering in cluster III of the NS phylogenetic tree. Rest of
DSO Specimens: rest of specimens sequenced in this study not individually
listed in this table. Identical amino acids are marked by a dot (.).
Table 12 Primers used in this study
Primer
name










UniB* AGC AGA AGC - All
HA 30 F§ CTA CTC ATG GTA GTA ACA TCC 709 bp HA
HA 749R§ YGG GAA GCC ACC AAT CTG
AGA AAC
HA 471 F§ ACC TCA GGA TCT TGC CCT AAC G 689 bp
HA1169R§ TGT GTA TCC GTG CCA ACC TGC AAT
HA 999 F§ AAA GCC ATA GGA AAT TGC CCA 841 bp
HA 1840R§ TCA ATA ACG TTT CTT TGT AAT
HA F⊥ TAT TCG TCT CAG GGA GCA GAA GCA
GAG CAT TTT CTA ATA TC
1840 bp
HA R⊥ ATA TCG CTC CGT ATT AGT AGT AAC
AAG AGC ATT TTT C
NA 21FΔ GCT ACC TTC AAC TAT ACA AAC G 547 bp NA
NA 568R§ TAC CAT CAT GGC ATG CGG A
NA 361 F§ GCT CCC TTG ATA ATA AGG GAA CC 477 bp
NA 838R§ ATG TTC TAC TCT TCC TGT TGG
NA 716 F§ GGG GGA RAT TGT TAT CTT ATG 789 bp
NA 1505R§ TTT CAG AAA CAA TTA AKT TCA GTA
AGG
NA F⊥ TAT TCG TCT CAG GGA GCA GAA
GCA GAG CA
1505 bp
NA R⊥ ATA TCG CTC CGT ATT AGT AGT
AAC AAG AGC ATT TT
NS 376R§ CTG GTG TTG AAG GGT AAT - NS
NS 700R§ AT CTT CTT CAT CCT CCA CTG TAA -
NS F⊥ TAT TCG TCT CAG GGA GCA GAA
GCA GAG GAT TTG TTT AGT C
1053 bp
NS R⊥ ATA TCG TCT CGT ATT AGT AGT
AAC AAG AGG ATT TTT AT
*Taken from Zou et al., [73].
⊥Taken from Hoffmann et al., 2000 [74].
§In-house designed primers.
ΔTaken from Tsai, 2006 [89].
♦Taken from Krafft et al., 2005 [90].
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http://www.biomedcentral.com/1756-0500/7/863and 50°C respectively and all with an elongation time of
1 min.
Non Structural (NS) gene
The full NS gene segment was amplified from the syn-
thesized cDNA using primers NS F and NS R (Table 12)
[74]. The thermocycling conditions required an anneal-
ing temperature of 62°C and an elongation temperature
of 72°C for 10 minutes. The NS gene segment was se-
quenced directly using primers NSF, NSR as well as
NS700R and NS376R (Table 12).Sequencing and bioinformatics
Eluted PCR products were sent to 1st BASE Singapore
for sequencing. Each PCR fragment was gel-extracted
and purified before subjecting to sequencing using the
ABI big dye with the respective PCR primers. The DNA
sequences of each fragment were assembled using Seq-
Man program (DNASTAR). For each of the HA, NA and
NS1 genes, the nucleotide sequences were aligned with
Clustal W from MegAlign software (DNASTAR) and the
Table 13 Touchdown PCR thermocycling conditions
Initial denaturation 94°C 2 min
Touchdown 11 cycles 94°C 30 sec
55°C 30 sec −1°C/cycle
68°C 2 min
Denaturation 40 cycles 94°C 30 sec
Annealing 4x8°C 30 sec
Extension 68°C 2 min
Final extension 68°C 10 min
Holding 12°C forever
All the PCR conditions in this study are touchdown PCR, with adjustments to
the annealing temperatures, and extension times.
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http://www.biomedcentral.com/1756-0500/7/863phylogenetic trees were next generated using the
Neighbour-Joining algorithm. The number of bootstrap
replications was set to 1000 and bootstrap values were
labelled on the tree branches [75]. The same software was
used to locate the positions of the correct open reading
frames (ORFs) and the amino acid sequences were next
translated. Sequence analysis was performed with closely
related sequences obtained with the NCBI blast search,
and the vaccine strains for years 2004–2013 [9,76-88]
(Tables 7 and 8).
Availability of supporting data
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supporting the phylogenetic trees in this study have been
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KC844196. The phylogenetic trees generated for this study
have also been uploaded to the TreeBase repository with
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